Centivax

Summary

Centivax, a Silicon Valley biotechnology startup focused on developing a universal flu vaccine using mRNA technology, secured $45 million in Series A funding led by Future Ventures. The company is progressing into Phase 1 human trials, having already conducted animal testing.